96 related articles for article (PubMed ID: 14501508)
1. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.
House MG; Herman JG; Guo MZ; Hooker CM; Schulick RD; Lillemoe KD; Cameron JL; Hruban RH; Maitra A; Yeo CJ
Ann Surg; 2003 Sep; 238(3):423-31; discussion 431-2. PubMed ID: 14501508
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior.
House MG; Guo M; Efron DT; Lillemoe KD; Cameron JL; Syphard JE; Hooker CM; Abraham SC; Montgomery EA; Herman JG; Brock MV
J Gastrointest Surg; 2003 Dec; 7(8):1004-14; discussion 1014. PubMed ID: 14675710
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas.
Guo M; Jia Y; Yu Z; House MG; Esteller M; Brock MV; Herman JG
Discov Med; 2014 Feb; 17(92):67-73. PubMed ID: 24534469
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of tumor suppressor genes methylation in circulating tumor DNA of patients with pancreatic cancer.
Xin W; Tu S; Yi S; Xiong Y; Fang K; Sun G; Xiao W
Gene; 2024 Mar; 897():148078. PubMed ID: 38097094
[TBL] [Abstract][Full Text] [Related]
5. ABERRANT METHYLATION OF CANCER-RELATED GENES IN VIETNAMESE BREAST CANCER PATIENTS: ASSOCIATIONS WITH CLINICOPATHOLOGICAL FEATURES.
Dieu Vuong L; Ngoc Nguyen Q
Exp Oncol; 2023 Oct; 45(2):195-202. PubMed ID: 37824772
[TBL] [Abstract][Full Text] [Related]
6. The role of the CDH1 promoter hypermethylation in the axillary lymph node metastasis and prognosis.
Jung SP; Kim S; Nam SJ; Kim I; Bae JW
J Breast Cancer; 2013 Mar; 16(1):16-22. PubMed ID: 23593077
[TBL] [Abstract][Full Text] [Related]
7. Quantitative detection of
Duppel U; Woenckhaus M; Schulz C; Merk J; Dietmaier W
Oncol Lett; 2016 Oct; 12(4):3004-3012. PubMed ID: 27698890
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.
Saleh Z; Moccia MC; Ladd Z; Joneja U; Li Y; Spitz F; Hong YK; Gao T
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279330
[TBL] [Abstract][Full Text] [Related]
9. Prediction of disease-free survival of N1/2 non-small cell lung cancer after adjuvant chemotherapy by the biomarker RPMB.
An N; Yang X
Heliyon; 2023 Jul; 9(7):e18266. PubMed ID: 37501955
[TBL] [Abstract][Full Text] [Related]
10. Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine.
Ehsanullah S; Trikalinos NA
Endocr Oncol; 2022 Jan; 2(1):K1-K4. PubMed ID: 37435465
[TBL] [Abstract][Full Text] [Related]
11. The role of DNA methylation in human pancreatic neuroendocrine tumours.
English KA; Thakker RV; Lines KE
Endocr Oncol; 2023 Jan; 3(1):e230003. PubMed ID: 37434653
[TBL] [Abstract][Full Text] [Related]
12. Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics.
Choi JH; Paik WH
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556070
[TBL] [Abstract][Full Text] [Related]
13. Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation.
Shen X; Wang X; Lu X; Zhao Y; Guan W
Front Oncol; 2022; 12():967071. PubMed ID: 36248960
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors.
Crabtree JS
Front Oncol; 2022; 12():901435. PubMed ID: 35747820
[TBL] [Abstract][Full Text] [Related]
15. Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.
Ban X; Mo S; Lu Z; Jia C; Shao H; Chang X; Mao X; Zhang Y; Pang J; Zhang Y; Yu S; Chen J
Endocrine; 2022 Sep; 77(3):538-545. PubMed ID: 35708896
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging.
Manneh Kopp R; Espinosa-Olarte P; Alonso-Gordoa T
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626118
[TBL] [Abstract][Full Text] [Related]
17. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
[TBL] [Abstract][Full Text] [Related]
18. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review).
Ciobanu OA; Martin S; Fica S
Exp Ther Med; 2021 Dec; 22(6):1479. PubMed ID: 34765020
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy in Neuroendocrine Tumors.
Das S; Al-Toubah T; Strosberg J
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638356
[TBL] [Abstract][Full Text] [Related]
20. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes.
Wu W; Liu Y; Zeng S; Han Y; Shen H
J Hematol Oncol; 2021 Oct; 14(1):160. PubMed ID: 34620200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
